AstraZeneca

News

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer.

News

AZ, MSD's Koselugo is first EU therapy for neurofibromatosis

The European Commission has approved AstraZeneca and MSD's Koselugo for a rare genetic condition that causes tumours to develop on the covering of nerve cells, leading to disfigurement and

News

Farxiga faces first heart failure rival as EU OKs Boehringer...

AstraZeneca's SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lil

News

EU and AZ both claim victory in COVID jab supply lawsuit

A court in Belgium has ordered AstraZeneca to deliver additional doses of its COVID-19 vaccine to EU member states by 27 September, although far fewer than the amount sought by the European

News

Ambrx tries another IPO as it chases down HER2 rivals

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, it

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ's COVID jab tackles delta variant, but antibody fails cli...

The delta variant of COVID-19 may be holding back the lifting of lockdown restrictions in the UK, but there is some good news – the AstraZeneca/Oxford University vaccine seems to offer a hi

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

AZ, MSD's Koselugo is first EU therapy for neurofibromatosis

Farxiga faces first heart failure rival as EU OKs Boehringer...

EU and AZ both claim victory in COVID jab supply lawsuit

Ambrx tries another IPO as it chases down HER2 rivals

AZ's COVID jab tackles delta variant, but antibody fails cli...

Gilead strikes again, penning $5bn deal to buy Tubulis

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks